Gene expression profiles of late colonic Crohn's disease

Journal of Medicine

Volumn 35, Issue 1-6, 2004, Pages 233-255

  Srivastava, Maya D ^a,c   Kulaylat, Mahmoud N ^b  

^a Erie County Medical Center ^*  (United States)

^b ERIE COUNTY MEDICAL CENTER   (United States)

^c Center for Digestive Allergic and Immunologic Diseases   (United States)

Author keywords

CD potential variability and individualized management; Colon specimens; Crohn's disease; DEFA6; Downregulated genes; Genes; Genetic filter; Genetic programming; IL 8; MMP 1; PAP; Patient; Phospholipase A2; PTN; REG1A; REG1B; RT PCR; S100 susceptibility

Indexed keywords

CALCIUM BINDING PROTEIN; DEFENSIN; GENE PRODUCT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PANCREATITIS ASSOCIATED PROTEIN; PHOSPHOLIPASE A2; PROTEIN S 100; REGENERATING PROTEIN 1 ALPHA; REGENERATING PROTEIN 1 BETA; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DEFA5 GENE; DEFA6 GENE; DISEASE PREDISPOSITION; GENE; GENE EXPRESSION PROFILING; GW112 GENE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REG1A GENE; REG1B GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE;

ADULT; CHRONIC DISEASE; COLON; CROHN DISEASE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 35348814325     PISSN: 00257850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ahmad T, Armuzzi A, Bunce M, et al. (2002). The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterol. 122: 854-866.
2. Bals, R. (2001). Epithelial antimicrobial peptides in host defense against infection. Respir Res. 1: 141-150.
3. Banks C, Bateman A, Payne R, et al. (2003). Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. Journal of Pathology. 199:28-35.
4. Basik M, Mousses S, Trent J. (2003). Integration of genomic technologies for accelerated cancer drug development. BioTechniques. 35:580-593.
5. Chang JC, Wooten EC, Tsimeizon A, et al. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet. 362: 362-369.
6. Chomczynski P, Sacchi N. (1987). Single step method of RNA isolation by acid guanidinium thiocyanate phenol-chloroform extraction. Analyt Biochem. 162:156-159.
7. Cunliffe RN, Kamal M, Rose FRAJ, et al. (2002). Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J Clin Pathol. 55:298-304.
8. Cuthbert AP, Fisher SA, Mirza MM, et al. (2002).The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterol. 122: 867-874.
9. Desjeux A, Barthet M, Barthellemy S, et al. (2002). Serum measurements of pancreatitis associated protein in active Crohn's disease with ileal location. Gastoenterol Clin Biol. 26:23-28.
10. Dieckgraefe B, Stenson W, Krzenik JR, et al. (2000). Analysis of mucosal gene expression in inflammatory bowel disease by parallel oliogonucleotide arrays. Physical Genomics. 4: 1-11.
11. El-Zaatari F, Osata MS, Graham DY. (2001). Etiology of Crohn's disease: the role of Mycobacterium avium paratuberculosis. Trends in Molecular Medicine. 7: 247-252.
12. Hooper LV, Gordon JI. (2001). Commensal host-bacterial relationships in the gut. Science. 292:1115-1118.
13. Jelinek DF, Tschumper RC, Stolovitzky GA, et al. (2003). Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Molecular Cancer Res. 1:346-361.
14. Lawrence, I.C., Fiocchi, C., Chakravarti, S. (2001). Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Human Molecular Genetics. 10: 445-456.
15. Luo JH, Yu YP, Cieply K, et al. (2002). Gene expression analysis of prostate cancers. Molecular Carcinogenesis. 33:25-35.
16. Michaud AD, Neut C, Barnich N, et al. (1998). Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterol. 115:1405-1413.
17. Nielsen OH, Vainer B, Madson SM, et al. (2000). Established and emerging biological activity markers of inflammatory bowel disease. Amer J Gastroenterol. 95:359-367.
18. Ouellette A, Bevins C (2001). Paneth cell defensins and innate immunity of the small bowel. Inflamm Bowel Dis. 7:43-50.
19. Roth J, Vogl T, Sorg C, et al. (2003). Phagocyte specific S100 proteins; a novel group of proinflammatory molecules. Trends in Immunology. 24:155-158.
20. Sandborn WJ, Targan SR. (2002). Biologic therapy of inflammatory bowel disease. Gastroenterol. 122:1592-1608.
21. Schoch C, Kohlmann A, Schnittger S, et al. (2002). Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci. 99:10008-10013.
22. Shinozaki S, Nakamura T, Iimura M, et al. (2001). Upregulation of Regla and GW 112 in the epithelium of inflamed colonic mucosa. Gut. 48: 623-629.
23. Staros EB. (2003). Molecular discoveries alter our view of inflammatory bowel disease. A review from scientific, clinical, and laboratory perspectives. Am J Clin Pathol. 119: 524-539.
24. Stediler L. (2001). Microbiological and immunological strategies for treatment of inflammatory bowel disease. Microbes and Infection. 3:1157-66.
25. Swidsinski A, Ladhoff A, Pernthaler A, et al. (2002). Mucosa flora in inflammatory bowel disease. Gastroenterol. 122:44-54.
26. Vadas P, Pruzanski W. (1986). Role of secretory phospholipases A2 in the pathobiology of disease. Lab Invest. 55:391-404.
27. Vadas P. (1986). Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram negative septic shock. J Lab Clin Med. 104:873-881.
28. Wright G, Tan B, Rosenwald A, et al. (2003). A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci. 100:9991-9996.
29. Yamakawa T, Kurosawa N, Kadomatsu K, et al. (1999). Levels of expression of pleiotrophin and protein tyrosine phosphatase are decreased in human colorectal cancers. Cancer Letters. 135: 91-96.